The present study reports elevated levels of endotoxin/lipopolysaccharide (LPS) concentrations in plasma from patients with sporadic amyotrophic lateral sclerosis (sALS) and Alzheimer's (AD) as compared to healthy controls. Levels of plasma LPS showed a significant positive correlation with degree of blood monocyte/macrophage activation in disease groups and was most elevated in patients with advanced sALS disease. There was a significant negative relationship between plasma LPS and levels of monocyte/ macrophage IL-10 expression in sALS blood. These data suggest that systemic LPS levels and activated monocyte/macrophages may play significant roles in the pathogenesis of sALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disorder characterized by the progressive loss of anterior-lateral horn spinal cord motor neurons leading to weakness and the eventual death of affected individuals. Although inflammatory mechanisms and immune activation have been considered as common components of the pathogenesis of ALS (Alexianu et al., 2001; Graves et al., 2004; Henkel et al., 2004; McGeer and McGeer, 2002; Simpson et al., 2004) , the relevance of these processes to pathogenesis is unknown.
Endotoxin/lipopolysaccharide (LPS), is a potent inflammatory stimulus and immunostimulatory product (Takeda et al., 2003) and induces its effects through stimulation of CD14-bearing inflammatory cells (Flo et al., 2000; Tobias et al., 1999) . LPS associated toxicity is mediated through systemic monocyte/macrophage and endothelial cell activation, and release of inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) (Beutler et al., 1985; Danner et al., 1991; Okusawa et al., 1988; Tracey et al., 1986) . The effects of LPS are mediated primarily through Toll-Like Receptor 4 (TLR4).
Increased levels of proinflammatory cytokines, such as MCP-1 ( Baron et al., 2005; Henkel et al., 2004; Simpson et al., 2004; Wilms et al., 2003; Zhang et al., 2006), and IL-6 (Ono et al., 2001; Sekizawa et al., 1998) have been reported in cerebral spinal fluid (CSF) and sera in patients with ALS. More recently, elevated levels of TNF-α have been observed in the blood of ALS patients (Babu et al., 2008; Cereda et al., 2008; Poloni et al., 2000) . Our previous studies on blood specimens from patients with sporadic ALS (sALS) found elevated levels of abnormally activated monocyte/macrophages as compared to controls (Zhang et al., 2005) . These data taken together suggested a potential role for LPS as a systemic monocyte activator in the pathogenesis of ALS. Therefore, the objectives of this study were: 1) to quantify the levels of plasma LPS in patients with sALS as compared to control groups, 2) to test whether levels of plasma LPS would correlate with monocyte activation and/or monocyte IL-10 (a regulator of activation) expression in blood, and 3) to determine if LPS levels in plasma correlated with clinical stage of disease in sALS.
Materials and methods

Subjects
Twenty-three patients diagnosed with sALS (7 females and 16 males, mean age 59.2 ± 8.7 years) by El Escorial criteria (Brooks, 1994) at the Forbes Norris MDA/ALS Research Center (San Francisco, California, USA) had blood drawn in accordance with the CPMC (California Pacific Medical Center) and UCSF committees on human research guidelines, coordinated by the UCSF AIDS and Cancer Specimen Resource (ACSR) program and excluded patients with any evidence for intercurrent infection. The Revised ALS Functional Rating Scale (ALSFRS-R), scored 0-48, was used to evaluate overall patient functional status (Cedarbaum et al., 1999) . All scores were updated within a month of blood testing. Demographic and medication Journal of Neuroimmunology 206 (2009) 121-124 
